Clinical bottom line
Male genital lichen sclerosus (MGLSc) is a chronic inflammatory dermatosis that can cause significant morbidity including phimosis, urethral strictures, and scarring. Conventional treatments such as potent topical corticosteroids remain first-line but often fail in refractory cases. Emerging therapies, notably 5-aminolevulinic acid photodynamic therapy (ALA-PDT) and mesenchymal stem cell (MSC) therapy, show promise in improving symptoms and histopathological features in refractory MGLSc. However, current evidence is limited to small, early-phase studies, and safety profiles require further validation. These novel approaches warrant cautious consideration as adjuncts or alternatives in patients unresponsive to standard care.
What the evidence shows
MGLSc is characterized by chronic inflammation and sclerosis of the genital skin, with a poorly understood etiology involving autoimmune and possibly infectious components (Mangera et al., 2016). Traditional management focuses on high-potency topical corticosteroids, which can control symptoms but may not reverse established fibrosis or prevent progression in refractory cases (Hall et al., 2018).
Two novel therapeutic modalities have recently been investigated:
- 5-Aminolevulinic Acid Photodynamic Therapy (ALA-PDT):
Shi et al. (2025) and Zhang et al. (2025) independently reported on the efficacy and safety of ALA-PDT in patients with refractory genital lichen sclerosus. Both studies demonstrated significant symptomatic improvement, reduced lesion size, and histological amelioration after multiple treatment sessions. ALA-PDT leverages photosensitizer-induced reactive oxygen species to target inflammatory and fibrotic cells selectively. Adverse events were generally mild and transient, including local erythema and discomfort. These findings suggest ALA-PDT as a potential non-invasive alternative for patients failing topical steroids.
- Mesenchymal Stem Cell (MSC) Therapy:
Laino et al. (2024) described subcutaneous adipose tissue-derived MSC therapy in a small cohort of refractory MGLSc patients. MSC treatment was associated with marked clinical improvement, decreased inflammation, and partial restoration of normal skin architecture. The immunomodulatory and regenerative properties of MSCs may address the underlying pathogenic mechanisms more effectively than anti-inflammatory agents alone. Safety data were favorable, with no serious adverse events reported during short-term follow-up.
Additional epidemiological insights highlight the possible role of human papillomavirus (HPV) DNA in MGLSc pathogenesis, with Kravvas et al. (2023) documenting HPV prevalence in affected tissues. This may open avenues for antiviral or vaccine-based adjunct therapies, although clinical implications remain speculative.
Caveats and uncertainty
The current evidence base for novel therapies in refractory MGLSc is limited by small sample sizes, lack of randomized controlled trials, and short follow-up durations. Both ALA-PDT and MSC therapy studies are preliminary and may be subject to selection bias and placebo effects. Long-term safety, optimal dosing schedules, and comparative effectiveness against established treatments are not yet established.
Furthermore, the heterogeneity of MGLSc presentation and severity complicates generalizability. The potential for malignant transformation in chronic MGLSc underscores the need for careful monitoring regardless of therapy. The role of HPV in disease progression is not fully elucidated and requires further mechanistic and clinical investigation.
How this may change practice
For urologists managing refractory MGLSc, awareness of emerging therapies such as ALA-PDT and MSC therapy is important as they may offer alternatives when conventional topical corticosteroids fail. Referral to specialized centers with access to these modalities could be considered in selected patients after thorough counseling about the experimental nature and limited evidence.
These novel treatments may complement existing regimens, potentially improving quality of life and reducing complications. However, routine adoption should await larger, controlled studies confirming efficacy and safety. Meanwhile, continued emphasis on early diagnosis, aggressive topical therapy, and vigilant surveillance for malignant transformation remains paramount.